Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1994 Mar;47(3):240–244. doi: 10.1136/jcp.47.3.240

Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer.

S Detre 1, N King 1, J Salter 1, K MacLennan 1, J A McKinna 1, M Dowsett 1
PMCID: PMC501903  PMID: 8163696

Abstract

AIMS--(i) To assess the validity of an immunocytochemical technique for detecting pS2 protein in paraffin wax embedded tissue; (ii) to provide further data on the relation between pS2 protein and oestrogen receptor (ER) and progesterone receptor (PgR). METHODS--Breast cancer excision biopsy specimens were obtained from 35 previously untreated patients. An immunoradiometric assay was compared with an immunohistochemical method for measuring pS2 protein. ER and PgR were measured in cytosol fractions by enzyme immunoassay and the relation between the presence of these receptors and pS2 protein was assessed before and after subdivision of the women into groups of over or under 50 years of age. RESULTS--A good correlation was seen between the immunoradiometric and immunohistochemical methods for pS2 protein measurement (r = 0.84; p = 0.0001). Log-transformed data showed a significant correlation between increasing values of ER and pS2 protein (r = 0.45; p = 0.006) and to a lesser extent between pS2 protein and PgR (r = 0.38; p = 0.03). Correlations were also shown between pS2+ and PgR+ status (p = 0.01), and between ER and PgR positivity (p = 0.05; Fisher's exact test). pS2+ protein status was only associated with ER+ status in patients aged 50 years or less. CONCLUSIONS--The two methods for pS2 analysis are virtually interchangeable. This provides strong support for using immunohistochemistry for pS2 in paraffin wax embedded tissue. The association with ER positivity and pS2+ protein status only in the premenopausal patients may be due to the higher levels of oestrogenic stimuli in that group.

Full text

PDF
240

Images in this article

242Image
on p.242

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexieva-Figusch J., Van Putten W. L., Blankenstein M. A., Blonk-Van Der Wijst J., Klijn J. G. The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer. Cancer. 1988 Feb 15;61(4):758–768. doi: 10.1002/1097-0142(19880215)61:4<758::aid-cncr2820610421>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  2. Berger U., Wilson P., Thethi S., McClelland R. A., Greene G. L., Coombes R. C. Comparison of an immunocytochemical assay for progesterone receptor with a biochemical method of measurement and immunocytochemical examination of the relationship between progesterone and estrogen receptors. Cancer Res. 1989 Sep 15;49(18):5176–5179. [PubMed] [Google Scholar]
  3. Cavailles V., Garcia M., Rochefort H. Regulation of cathepsin-D and pS2 gene expression by growth factors in MCF7 human breast cancer cells. Mol Endocrinol. 1989 Mar;3(3):552–558. doi: 10.1210/mend-3-3-552. [DOI] [PubMed] [Google Scholar]
  4. Clark G. M., McGuire W. L., Hubay C. A., Pearson O. H., Marshall J. S. Progesterone receptors as a prognostic factor in Stage II breast cancer. N Engl J Med. 1983 Dec 1;309(22):1343–1347. doi: 10.1056/nejm198312013092240. [DOI] [PubMed] [Google Scholar]
  5. Foekens J. A., Rio M. C., Seguin P., van Putten W. L., Fauque J., Nap M., Klijn J. G., Chambon P. Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res. 1990 Jul 1;50(13):3832–3837. [PubMed] [Google Scholar]
  6. Fuqua S. A., Fitzgerald S. D., Chamness G. C., Tandon A. K., McDonnell D. P., Nawaz Z., O'Malley B. W., McGuire W. L. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 1991 Jan 1;51(1):105–109. [PubMed] [Google Scholar]
  7. Goussard J., Lechevrel C., Roussel G., Cren H., Bera O., Sala M. Immunoradiometric assay of pS2 protein in breast cancer cytosols. Clin Chem. 1991 Oct;37(10 Pt 1):1759–1762. [PubMed] [Google Scholar]
  8. Harland R. N., Barnes D. M., Howell A., Ribeiro G. G., Taylor J., Sellwood R. A. Variation of receptor status in cancer of the breast. Br J Cancer. 1983 Apr;47(4):511–515. doi: 10.1038/bjc.1983.81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Helin H. J., Isola J. J., Helle M. J., Adlercreutz H. Influence of endocrine status on biochemical and immunocytochemical estrogen and progesterone receptor assays in breast cancer patients. Breast Cancer Res Treat. 1988 Sep;12(1):67–73. doi: 10.1007/BF01805742. [DOI] [PubMed] [Google Scholar]
  10. Helin H., Isola J., Helle M., Koivula T. Discordant results between radioligand and immunohistochemical assays for steroid receptors in breast carcinoma. Br J Cancer. 1990 Jul;62(1):109–112. doi: 10.1038/bjc.1990.239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Horwitz K. B., McGuire W. L. Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. J Biol Chem. 1978 Apr 10;253(7):2223–2228. [PubMed] [Google Scholar]
  12. Hähnel E., Robbins P., Harvey J., Sterrett G., Hähnel R. Expression of the pS2 gene in breast tissues assessed by pS2-mRNA analysis and pS2-protein radioimmunoassay. Breast Cancer Res Treat. 1992;24(1):71–74. doi: 10.1007/BF01832360. [DOI] [PubMed] [Google Scholar]
  13. King W. J., Greene G. L. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature. 1984 Feb 23;307(5953):745–747. doi: 10.1038/307745a0. [DOI] [PubMed] [Google Scholar]
  14. Luqmani Y. A., Campbell T., Soomro S., Shousha S., Rio M. C., Coombes R. C. Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast. Br J Cancer. 1993 Apr;67(4):749–753. doi: 10.1038/bjc.1993.136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Masiakowski P., Breathnach R., Bloch J., Gannon F., Krust A., Chambon P. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res. 1982 Dec 20;10(24):7895–7903. doi: 10.1093/nar/10.24.7895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. May F. E., Westley B. R. Cloning of estrogen-regulated messenger RNA sequences from human breast cancer cells. Cancer Res. 1986 Dec;46(12 Pt 1):6034–6040. [PubMed] [Google Scholar]
  17. McGuire W. L., Clark G. M. The prognostic role of progesterone receptors in human breast cancer. Semin Oncol. 1983 Dec;10(4 Suppl 4):2–6. [PubMed] [Google Scholar]
  18. Mori K., Fujii R., Kida N., Takahashi H., Ohkubo S., Fujino M., Ohta M., Hayashi K. Complete primary structure of the human estrogen-responsive gene (pS2) product. J Biochem. 1990 Jan;107(1):73–76. doi: 10.1093/oxfordjournals.jbchem.a123014. [DOI] [PubMed] [Google Scholar]
  19. Nunez A. M., Jakowlev S., Briand J. P., Gaire M., Krust A., Rio M. C., Chambon P. Characterization of the estrogen-induced pS2 protein secreted by the human breast cancer cell line MCF-7. Endocrinology. 1987 Nov;121(5):1759–1765. doi: 10.1210/endo-121-5-1759. [DOI] [PubMed] [Google Scholar]
  20. Pichon M. F., Milgrom E. Oestrogen receptor negative-progesterone receptor positive phenotype in 1,211 breast tumours. Br J Cancer. 1992 Jun;65(6):895–897. doi: 10.1038/bjc.1992.187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Piggott N. H., Henry J. A., May F. E., Westley B. R. Antipeptide antibodies against the pNR-2 oestrogen-regulated protein of human breast cancer cells and detection of pNR-2 expression in normal tissues by immunohistochemistry. J Pathol. 1991 Feb;163(2):95–104. doi: 10.1002/path.1711630204. [DOI] [PubMed] [Google Scholar]
  22. Rio M. C., Bellocq J. P., Gairard B., Rasmussen U. B., Krust A., Koehl C., Calderoli H., Schiff V., Renaud R., Chambon P. Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9243–9247. doi: 10.1073/pnas.84.24.9243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Schwartz L. H., Koerner F. C., Edgerton S. M., Sawicka J. M., Rio M. C., Bellocq J. P., Chambon P., Thor A. D. pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res. 1991 Jan 15;51(2):624–628. [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES